Tel.: +34 91 736 2385
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name


WFH 2016 World Congress


24-28 July 2016 Orlando
Discussion forum - WFH 2016 World Congress
    Topic - Pharmacokinetics

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
 Thread / Poster  Author  Replies  Last reply
Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated adult, adolescent, and paediatric patients with haemophilia B results from two phase 3 trials  Jasper Jacobsen 1      7/21/2016 12:41:00 PM  
Pharmacokinetic (PK) profiles in boys with hemophilia A assessed using a population PK Program (myPKFiT) and WinNonlin  Koyo Usuba 1      7/18/2016 2:41:00 PM  
The pharmacokinetics characteristics of plasma-derived and recombinant FVIII products in Chinese children with severe hemophilia A.  Zhenping Chen 1      7/7/2016 8:11:00 PM  
In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients  Tim Preijers 1      7/7/2016 2:16:00 PM  
Comparison of pharmacokinetic (PK)-guided prophylactic dosing tools in hemophilia A - a pilot study  Tim Preijers 1      7/7/2016 2:05:00 PM  
Is weight-based adjustment of factor VIII dosage required for underweight or overweight Japanese patients with hemophilia A?  Megumi Noguchi 1      7/7/2016 1:22:00 PM  
Pharmacokinetic (PK)-guided daily dosing: a significant reduction in weekly clotting factor VIII consumption  Iris van 1      7/7/2016 10:05:00 AM  
Population pharmacokinetic model of recombinant single-chain factor VIII (rVIII SingleChain) in patients with hemophilia A  Ying Zhang 1      7/5/2016 4:24:00 PM  
Pharmacokinetics of a plasma-derived von VWF/FVIII concentrate (Voncento) in adult/adolescent and pediatric subjects with severe hemophilia A (SWIFT-HA and SWIFTLY-HA studies)  Wilfried Seifert 1      7/4/2016 4:25:00 PM  
Population pharmacokinetic modeling of factor IX activity after administration of nonacog alfa in patients with hemophilia B  Joan Korth-Bradley 1      6/28/2016 3:27:00 PM  
Single center clinical and pharmacokinetic experience with long-acting recombinant factor VIII (rFVIIIFx) and IX (rFIXFc)  Devin Malik 1      6/26/2016 12:53:00 AM  

Most viewed poster for this congress
Poster: 13
Visits: 590
Title: Algorithmic evidence-based phenotype screening and collaborative approach to attacking symptoms of nonadherence in patients with bleeding disorders
Authors: Jay Bryant-Wimp , Jay Bryant-Wimp, RPh
Centre: Integrite Solutions

Poster most viewed in this topic
Poster: 142
Visits: 21
Title: Population pharmacokinetic model of recombinant single-chain factor VIII (rVIII SingleChain) in patients with hemophilia A
Authors: YING ZHANG , J Roberts, D Bensen-Kennedy, A Veldman, K St Ledger, J Sidhu
Centre: CSL Behring


Logo Draft
Logo Cert